No standard treatment has been established for metastatic uveal melanoma (mUM). Immunotherapy is commonly used for this disease even though UM has not been included in phase III clinical trials with checkpoint inhibitors. Unfortunately, only a minority of patients obtain a clinical benefit with immunotherapy. The immunological features of mUM were reviewed in order to understand if immunotherapy could still play a role for this disease.
Keywords: IDO; PD-L1; checkpoint inhibitors; immunotherapy; ipilimumab; nivolumab; pembrolizumab; uveal melanoma.